Italia markets closed

ARVN May 2024 35.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,0500-0,1500 (-75,00%)
In data: 10:19AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,2000
Aperto0,0500
Denaro0,0000
Lettera0,0500
Prezzo d'esercizio35,00
Scadenza2024-05-17
Min-Max giorno0,0500 - 0,0500
Contratto - Min-MaxN/D
Volume2
Open Interest712
  • GlobeNewswire

    Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Bavdegalutamide is an investigational orally bioavailable PROTAC® androgen receptor (AR) degrader and is being developed as a potential treatment

  • GlobeNewswire

    Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g

  • GlobeNewswire

    Arvinas to Participate in Upcoming Investor Conferences

    NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Wells Fargo 2023 Healthcare Conference on Wednesday, September 6. Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the present